SecBot SecBot
Insider Cluster (4 insiders) ·Filed May 21, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $40.2M total
Actionable Insight • Neutral

Insider sales post-acquisition close are likely profit-taking, not a fundamental signal. Monitor for additional filings; the next 10-Q will update on deal integration. No immediate trading action warranted.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$156.50
T+0 close · May 21, 2026 · via day close
Latest settled
−1.45%
T+60 · $154.23
Vs SPY
−4.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $156.50entry
  2. T+1 · 6mo ago −0.50%α −1.08% · $155.72
  3. T+5 · 6mo ago +2.54%α +0.89% · $160.48
  4. T+20 · 5mo ago +3.27%α +3.44% · $161.62
  5. T+60 · 3mo ago −1.45%α −4.37% · $154.23

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two directors sold $40.2M in NBIX shares ($2.36M and $37.82M) within days of Neurocrine's $2.9B acquisition of Soleno Therapeutics closing on May 18, 2026. The sales represent 0.26% of market cap and follow option exercises by the same insiders, indicating routine profit-taking post-deal rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$40.2M
Insiders
4

Key Facts

  • Directors Richard F. Pops and Kevin Charles Gorman sold a combined $40.2M in open-market sales on May 15 and May 19, 2026.
  • Sales occurred after the close of Neurocrine's $2.9B acquisition of Soleno Therapeutics on May 18, 2026.
  • The total sale value is 0.26% of NBIX's $15.6B market cap, a modest amount.
  • Both insiders also exercised stock options around the same dates, converting non-cash awards into shares sold.

Financial Impact

$40.2M in insider sales, 0.26% of market cap

dilutioninsider ownership

Risk Factors

  • Further insider selling could appear, but at current magnitude it is not material.
  • Integration of Soleno's VYKAT XR may face commercial hurdles not yet reflected in insider behavior.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NBIX-1779405695847

Track record

30 reports on NBIX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 8h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026